Advancing Regulatory Science FDA discovery that Ad5 vector uses coagulation factor X to block complement proteins has major implications for gene therapy Common wisdom has held that the gene transfer vector adenovirus 5

First Page		Document Content
Molecular biology Immune system Applied genetics Viral vector Complement system Coagulation Gene therapy Antibody Vector Biology Gene delivery Coagulation system		Advancing Regulatory Science FDA discovery that Ad5 vector uses coagulation factor X to block complement proteins has major implications for gene therapy Common wisdom has held that the gene transfer vector adenovirus 5 Add to Reading List Source URL: www.fda.gov. Download Document from Source Website File Size: 181,60 KB Share Document on Facebook

	Development of a novel adeno-associated viral vector in combination with tolerogenic nanoparticles for the treatment of Ornithine Transcarbamylase Deficiency Giulia De Sabbata1, Florence Boisgerault2,3, Fanny Collaud2,3, DocID: 1v7ly - View Document
	Controlling Aedes aegypti and Aedes albopictus: Information for vector control programs Background yy Mosquito-borne viral diseases such as chikungunya, dengue, and Zika can cause similar symptoms, including fever with m DocID: 1uPwQ - View Document
	Speakers Boris Kantor, Ph.D. Assistant Professor and Viral Vector Core Director Duke University DocID: 1uirE - View Document
	MIT Committee on Assessment of Biohazards: Policy for Use of Lentiviral Vectors DocID: 1r6Cz - View Document
	BIO 5099: Molecular Biology for Computer Scientists (et al) Lecture 25: Biotechnology http://compbio.uchsc.edu/hunter/bio5099 DocID: 1qu56 - View Document